These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Frequency and predictors of contrast-induced nephropathy after angioplasty for chronic total occlusions. Aguiar-Souto P; Ferrante G; Del Furia F; Barlis P; Khurana R; Di Mario C Int J Cardiol; 2010 Feb; 139(1):68-74. PubMed ID: 19056138 [TBL] [Abstract][Full Text] [Related]
6. Contrast-induced nephropathy among Israeli hospitalized patients: incidence, risk factors, length of stay and mortality. Shema L; Ore L; Geron R; Kristal B Isr Med Assoc J; 2009 Aug; 11(8):460-4. PubMed ID: 19891232 [TBL] [Abstract][Full Text] [Related]
7. Contrast media induced nephropathy: definition, incidence, outcome, pathophysiology, risk factors and prevention. Feldkamp T; Kribben A Minerva Med; 2008 Apr; 99(2):177-96. PubMed ID: 18431326 [TBL] [Abstract][Full Text] [Related]
8. Outcomes of contrast-induced nephropathy: experience in patients undergoing cardiovascular intervention. McCullough P Catheter Cardiovasc Interv; 2006 Mar; 67(3):335-43. PubMed ID: 16489569 [TBL] [Abstract][Full Text] [Related]
9. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Dangas G; Iakovou I; Nikolsky E; Aymong ED; Mintz GS; Kipshidze NN; Lansky AJ; Moussa I; Stone GW; Moses JW; Leon MB; Mehran R Am J Cardiol; 2005 Jan; 95(1):13-9. PubMed ID: 15619387 [TBL] [Abstract][Full Text] [Related]
12. Prevention and treatment of contrast-induced nephropathy. Al-Ghonaim M; Pannu N Tech Vasc Interv Radiol; 2006 Jun; 9(2):42-9. PubMed ID: 17482099 [TBL] [Abstract][Full Text] [Related]
13. Radiologists' knowledge and perceptions of the impact of contrast-induced nephropathy and its risk factors when performing computed tomography examinations: a survey of European radiologists. Reddan D; Fishman EK Eur J Radiol; 2008 May; 66(2):235-45. PubMed ID: 17728089 [TBL] [Abstract][Full Text] [Related]
14. Hyperuricemia as a risk factor for contrast-induced nephropathy in patients with chronic kidney disease. Toprak O; Cirit M; Esi E; Postaci N; Yesil M; Bayata S Catheter Cardiovasc Interv; 2006 Feb; 67(2):227-35. PubMed ID: 16400673 [TBL] [Abstract][Full Text] [Related]
15. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Patti G; Nusca A; Chello M; Pasceri V; D'Ambrosio A; Vetrovec GW; Di Sciascio G Am J Cardiol; 2008 Feb; 101(3):279-85. PubMed ID: 18237585 [TBL] [Abstract][Full Text] [Related]
16. The incidence of contrast-induced nephropathy in trauma patients. Hipp A; Desai S; Lopez C; Sinert R Eur J Emerg Med; 2008 Jun; 15(3):134-9. PubMed ID: 18460952 [TBL] [Abstract][Full Text] [Related]
17. [Contrast nephropathy and its prevention]. Skulec R; Bĕlohlávek J; Kovárník T; Linhart A; Aschermann M Vnitr Lek; 2003 Feb; 49(2):127-33. PubMed ID: 12728580 [TBL] [Abstract][Full Text] [Related]
18. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Khanal S; Attallah N; Smith DE; Kline-Rogers E; Share D; O'Donnell MJ; Moscucci M Am J Med; 2005 Aug; 118(8):843-9. PubMed ID: 16084176 [TBL] [Abstract][Full Text] [Related]